Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Investing Activities: 2016-2024

Historic Cash from Investing Activities for Arcus Biosciences (RCUS) over the last 9 years, with Dec 2024 value amounting to -$84.0 million.

  • Arcus Biosciences' Cash from Investing Activities rose 372.41% to $79.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.0 million, marking a year-over-year increase of 379.44%. This contributed to the annual value of -$84.0 million for FY2024, which is 143.30% down from last year.
  • Per Arcus Biosciences' latest filing, its Cash from Investing Activities stood at -$84.0 million for FY2024, which was down 143.30% from $194.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Cash from Investing Activities ranged from a high of $194.0 million in FY2023 and a low of -$434.0 million during FY2020.
  • In the last 3 years, Arcus Biosciences' Cash from Investing Activities had a median value of -$84.0 million in 2024 and averaged -$101.0 million.
  • Per our database at Business Quant, Arcus Biosciences' Cash from Investing Activities plummeted by 10,225.00% in 2022 and then soared by 146.97% in 2023.
  • Arcus Biosciences' Cash from Investing Activities (Yearly) stood at -$434.0 million in 2020, then spiked by 99.08% to -$4.0 million in 2021, then crashed by 10,225.00% to -$413.0 million in 2022, then skyrocketed by 146.97% to $194.0 million in 2023, then tumbled by 143.30% to -$84.0 million in 2024.